­Sent by email only to: XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXX

XXXXXXX XXXXXXXXX XXXXXXXX XX XXXXXXXXXX XXX XXXXXXXX XXXXXXX

Lymphoma Action

XXXX XXXXXXXXX XXXXXXXX XXXXX XXXXXXXXX XXXXXXX

Leukaemia Care

19 April 2021

Dear XX XXXXXXXXX XXX XX XXXXXXXXX XXXXXXXX

**Re: Final Appraisal Document –** **Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]**

Thank you for lodging your appeal against the above Final Appraisal Document. I acknowledge receipt of your email dated 1 April 2021 confirming that you are happy to proceed with the response in my initial scrutiny letter. We will use your appeal letter and the initial scrutiny letter for the appeal.

NICE will now contact you to make arrangements for an oral appeal hearing, which is likely to be conducted remotely. Your appeal points will be shared in advance with any co-appellants, and you will in turn receive the appeal points that have been accepted from any co-appellants, to help with preparing for the appeal day. The chair of the appeal panel is likely to want to group points that raise similar issues to be taken together, so that the day can be conducted most effectively, and may be in touch in this regard.

Ordinarily appeals are conducted on the basis of the appellants’ written appeal letters, and the material generated during the appraisal process. Use of additional written material is discouraged, and the panel cannot receive any new evidence. If, exceptionally, you feel there is written material that will not be before the panel that you would wish to rely on you must let NICE know by return of letter, indicating what the material is, why it is desirable to submit it, and when it will be available, by no later than **Monday 26 April 2021**. Please note that the appeal panel cannot accept papers that are tabled late or ad hoc, as this affects the preparation of the panel and other parties for the appeal.

Yours sincerely

Tim Irish

Vice Chair

National Institute for Health and Care Excellence